AI4LUNGS
@AI4LUNGS
Followers
129
Following
127
Statuses
114
AI-based personalised care for #respiratory disease. Funded by 🇪🇺 @HorizonEU. The tweets reflect partners' views. The account is managed by @FutureNeedsEU.
Porto, Portugal
Joined January 2024
3 more days til the Clinical Validation Workshop! Exclusive to the AI4LUNGS Stakeholders! Check out more information on the workshop and the link to sign up! Be the change in the future of health care:
0
0
1
🎗️ Today is #WorldCancerDay—a reminder that early detection, research, and support save lives. Let’s stand together to raise awareness, break the stigma, and push for better care for all. Every action counts. 💜 #CancerAwareness
0
0
0
Developing digital solutions following the ethical principles in the healthcare sector is. Check out the AI4LUNGS Digital Ethics Principles:
0
0
0
Save the Date🚀 Join the AI4LUNGS Clinical Validation Workshop on AI tools for #lungdisease diagnosis, Feb 7th, 12:00-13:00 CET. Get involved, share insights, and shape the future of healthcare! #HorizonEurope
0
0
0
RT @FutureNeedsEU: Happening now. Lee Ingleton and Pavlos Zafiropoulos are representing our #HorizonEurope projects (@EnTrust_Horizon, @AI4…
0
1
0
AI4LUNGS is shaping the future of healthcare with ethical AI solutions for accurate diagnoses and personalized treatments. From lung disease detection to epilepsy treatment, AI tools empower healthcare professionals while ensuring patient trust. Read more:
0
0
0
In case you haven't follow AI4LUNGS's Newsletters on LinkedIn, be sure to do so!
0
0
0
Lung cancer is the leading cause of cancer-related deaths worldwide, but awareness can save lives. Early detection and innovative treatments are key to improving outcomes. Let's amplify the conversation about lung health and drive change. #LungCancerAwareness
When asked why I, someone without lung cancer, immerse myself in the YLC community—knowing the grief it brings—I always say: “I never wish I hadn’t met them. I only wish I had more time to know them.” RIP to my sweet friend, Linda. You deserved more. 💔 -Bianca
0
2
5
The interview with the AI4LUNGS Project Coordinator has over 1400 views on LinkedIn, it is now uploaded on Youtube! Check out the interview to see how we are using AI, while respecting GDPR and ethical practices in transforming lung disease treatment!
0
0
1
How do NSCLC patients view treatment toxicities & therapeutic drug monitoring with TKIs? A new study explores their perspectives, emphasizing the need for patient-centered care and robust evidence for guided dosing. #LungCancer #MedicalResearch
📰 A new study published in @TAMedOncol is lending critical insights into patient perspectives on treatment-related toxicities and therapeutic drug monitoring with TKIs for the treatment of NSCLC. ➡️ Learn more: #NSCLC #lcsm
0
0
2
Breathing is life, yet millions face constant struggles due to lung diseases. AI4LUNGS is transforming care in Europe with AI-powered tools better treatments. Read our latest Press Release: #HorizonEurope
0
0
1
🌬️Early awareness saves lives! Lung cancer often shows no symptoms until advanced stages, making education & early detection vital. Understanding risks, symptoms, & screening options empowers better outcomes. Let’s prioritise lung health!💙 #LungCancerAwareness #HealthMatters
🌬️ Anyone with lungs, can get lung cancer. 🫁 Thank you, Vassilis Gravaris, for raising awareness. Lung cancer doesn’t discriminate. Let’s support prevention, early diagnosis, and research. 🫁💪 #FairLifeLCC #LungCancer #LungCancerAwareness #HealthyLungs #AnyoneWithLungs
0
0
1
💡New insights on patient perspectives with TKIs for NSCLC! A study reveals patients often hesitate to report low-grade toxicities & feel uncertain about drug monitoring's impact on efficacy. Clear communication & robust evidence are key for patient confidence. #LungCancer #TKI
🫁 A new study published in @TAMedOncol is lending critical insights into patient perspectives on treatment-related toxicities and therapeutic drug monitoring with TKIs for the treatment of NSCLC. ➡️ Learn more: #NSCLC #lcsm
0
0
1
🚨Update from Genprex! Phase 1 of the Acclaim-3 trial for ES-SCLC is complete, with no dose-limiting toxicities. Phase 2 is now enrolling, aiming to evaluate 18-week progression-free survival with REQORSA® + Tecentriq®. Data presentation expected in 2025! #LungCancer
📰 The phase 1 dose escalation portion of the Acclaim-3 clinical trial has been completed, with an approval for opening the phase 2 expansion portion of the trial, according to an announcement from @genprex. ➡️ Learn more about the trial: #SCLC #lcsm
0
0
1
Congratulations on another achievement project funded by @EU_HaDEA ! Scientists, professionals in the health care fields, researchers, and stakeholders are working towards a better future for #healthcare!
EU-funded researchers have designed a 3D model of the thyroid from human stem cells, deepening our understanding of the endocrine system and reducing the need for animal trials. Read more about the #H2020 SCREENED project: #ResearchImpactEU
0
0
2
Join us in our latest blog post as we explore why engaging stakeholders is essential to driving meaningful progress in EU #healthcare. 👩🏼⚕️⤵
0
0
1
RT @CanAlliance_SYB: Our Clinical Director of the #TargetedLungHealthChecksProgramme talks through signs and symptoms for #LungCancerAwaren…
0
1
0
Our Clinical Partner, Jan F. Nygård from @kreftregisteret on the evolving role of #MachineLearning and #AI in #cancer care. 💻🩺
0
0
0
Are you working in respiratory healthcare?🫁👩⚕️AI4LUNGS is inviting professionals like you to join our Stakeholders Forum—a select group dedicated to advancing AI solutions in respiratory disease diagnosis and treatment.
0
0
1
RT @LungCancerEu: Announced as #LungCancerAwarenessMonth begins, the initiative will be funded by the Irish Cancer Society and is being led…
0
3
0